Phase 2 study examines dose reduction levels for zilovertamab vedotin in metastatic solid tumors, suggesting dosing adjustments may enhance treatment outcomes.
Supplemental Table S1. Dose Reduction Levels for the Twice Every 3 Weeks Dosing Schedule
No takes yet. Share an insight, caveat, or question.
Meric‐Bernstam et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: